The U.S. Food and Drug Administration (FDA) has given fast track designation to ELX-02, an investigational treatment for people with cystic fibrosis (CF) caused by nonsense mutations. This FDA designation aims to speed the development and regulatory review of potential treatments for serious or life-threatening diseases with an unmet medical need. It gives Eloxx Pharmaceuticals access to more […]The post ELX-02, Potential CF Nonsense Mutation Therapy, on FDA Fast Track appeared first on Cystic Fibrosis News Today Via https://hubpage.tumblr.com/post/661947918052392960
0 Comments
Leave a Reply. |
ABOUT USHi I am Ellie Matthew. I am driven and dedicated to learning and perfecting my work in various elds and providing value to any task I undertake. Entrepreneurial experiences give me insight into how businesses are run and what I can do to bring value. My ability to quickly adapt to any scenario and good communication skills help build lasting professional relationships. |